Top Stock Ideas Sent Daily — Join and Gain Your Edge
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Top Stock Ideas Sent Daily — Join and Gain Your Edge
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Analyst Color
This Analyst Sees More Than 25% Upside In Uber Thanks To Increased Food Delivery Penetration
BlackBerry's Path To Profitability In Question, Analyst Cites Cybersecurity Struggles and Sluggish IoT Growth
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
BlackBerry's Path To Profitability In Question, Analyst Cites Cybersecurity Struggles and Sluggish IoT Growth
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
ICE's Resilient Business Model and Technological Advancements Drive an Outperform Rating - Here's Why
Tesla 'Mojo Is Back,' Tech Analyst Dan Ives Says Ahead Of Q3 Deliveries
ICE's Resilient Business Model and Technological Advancements Drive an Outperform Rating - Here's Why
Tesla 'Mojo Is Back,' Tech Analyst Dan Ives Says Ahead Of Q3 Deliveries
Chesapeake Energy Set To Become Largest Natural Gas Producer In US, Says Analyst
Accenture Is A 'Key Beneficiary Of' GenAI: Analysts Raise Forecasts After Q4 Results
Read More...
Analyst Color Recent News
Costco's Strong Q4 Performance Sparks Mixed Analyst Reactions As Stock Slides
Costco's reported Q4 earnings beat on strong sales and gross margin expansion. Some analysts warn of earnings growth moderating ahead.
Micron's AI-Driven HBM Demand and Data Center Growth to Fuel Stock Upside, Analysts Say
NASDAQ: MU stock rose after Micron reported strong Q4 results, beating revenue and EPS estimates. Analysts raise price targets, expect continued growth.
Nordstrom Downgraded: Analyst Highlights Consumer Pressure And Potential M&A Impact
KeyBanc downgraded Nordstrom to Sector Weight, citing go-private deal speculation and mixed outlook amid consumer pressures and holiday promotions.
GE Vernova Set For $2.5B Free Cash Flow By 2026 Amid Energy Transition Boom, Bullish Analyst Says
Analyst initiates coverage on GEV with Buy rating and $300 price target, citing strong position in energy transition and growth potential.
Disney's Streaming Surge, Epic Games Deal Among Key Growth Drivers, Says Analyst
Needham analyst reiterates Buy rating for Disney with $110 price target based on DTC breakeven in 2024, new subscribers, investments, cash flow, and content value.
Meta's AI Breakthroughs Dominate Connect Event As Analyst Highlights Affordable Mixed-Reality Push
Meta's AI and AR advancements excite investors and tech enthusiasts. Recent events showcase their ambition to shape computing's future.
Salesforce Analyst Sees AI As A Tailwind, Stakeholders 'Fed Up' With Dual Mandate
Salesforce can maintain 10% growth for a couple of years, but there's a call for innovative products to sustain long-term expansion.
Palantir Bull Says AI Platform Will Be Valuation Changer Heading Into 2025, Calls For Incremental 20% Upside For Stock
A bullish analyst is extremely positive about Palantir's AIP platform and its adoption by enterprises.
Expect Healthy Online Spending This Holiday Season, Says Analyst: What To Know
BofA Securities says U.S. consumers are focused on value and sees Amazon and Walmart as well-positioned in the e-commerce industry reap the benefits heading into a holiday season of healthy consumer spending.
Fox Stock Thrives On Sports, Politics Strategy: Analyst Says It Will 'Weather Secular Headwinds'
A Fox analyst raises the price target ahead of the 2024 election with the media company set to benefit from politics and sports.
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
BioMarin Pharmaceutical aims to achieve $4 billion in revenue by 2027, driven by Voxzogo adoption, despite emerging competition from Ascendis Pharma. Goldman Sachs maintains a "Buy" rating with a $139 price target.
What's In Store For Nike In Q1? Analyst Highlights China Vs. North America Trends
Goldman Sachs maintains a Buy rating on Nike, anticipating healthy Q1 results but cautious on growth prospects amid mixed signals from China.
Why Is Global Payments Stock Diving On Wednesday?
Global Payments shares down on weaker FY25 EPS growth forecast. Company to return $7.5B to shareholders in next 3 years.